Search
FORGEN I GV2 Eliminierbare Vektoren zur T-Zell-Transformation
FORGEN I GV2 Eliminierbare Vektoren zur T-Zell-Transformation
FORGEN I GV1 Entwicklung von stringent und selektiv regulierten Expressionseinheiten
FORGEN I GV1 Entwicklung von stringent und selektiv regulierten Expressionseinheiten
FORGEN II VV10 Gentransfer into dendritic cells by recombinant polyoma capsids
FORGEN II VV10 Gentransfer into dendritic cells by recombinant polyoma capsids
FORGEN II VV9 Cytomegalovirus (CMV) vectors for generation of protective immune cells to treat CMV disease after bone marrow transplantation
FORGEN II VV9 Cytomegalovirus (CMV) vectors for generation of protective immune cells to treat CMV disease after bone marrow transplantation
FORGEN II VV8 Development of a Live Vaccine against Epstein- Barr Virus
FORGEN II VV8 Development of a Live Vaccine against Epstein- Barr Virus
FORGEN II VV7 Replication deficient herpesvirus vectors with shut-off function for T lymphocytes
FORGEN II VV7 Replication deficient herpesvirus vectors with shut-off function for T lymphocytes T lymphocytes mediate protective immunity against infectious pathogens and cancer cells. Novel…
FORGEN II VV6 Stringente regulation of suicid genes in human cells
FORGEN II VV6 Stringente regulation of suicid genes in human cells
FORGEN II VV5 Genomic Targeting of recombinant Adeno-Associated Virus
FORGEN II VV5 Genomic Targeting of recombinant Adeno-Associated Virus The adeno-associated virus (AAV) has promising features as a vector for somatic gene therapy, e.g. AAV displays a wide tropism,…
FORGEN II VV4 Foamy virus – derived vectors for somatic gene therapy
FORGEN II VV4 Foamy virus – derived vectors for somatic gene therapy
FORGEN II VV3 Identification of breastcancer –specific HERV promoters'
FORGEN II VV3 Identification of breastcancer –specific HERV promoters'